Global Graft Versus Host Disease (GVHD) Pipeline Review H2 2020

News provided by

Nov 05, 2020, 07:15 ET

DUBLIN, Nov. 5, 2020 /PRNewswire/ -- The "Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report provides an overview of the Graft Versus Host Disease (Immunology) pipeline landscape. The pipeline guide provides comprehensive information on the therapeutics under development for Graft Versus Host Disease (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Graft Versus Host Disease (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Graft Versus Host Disease (GVHD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 12, 38, 15, 3, 39, 8 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 1, 3, 13 and 1 molecules, respectively.

The pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision-making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope of the report:

The pipeline guide provides a snapshot of the global therapeutic landscape of Graft Versus Host Disease.
The pipeline guide reviews pipeline therapeutics by companies and universities/research institutes based on information derived from company and industry-specific sources.
The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
The pipeline guide reviews key companies involved in Graft Versus Host Disease (Immunology) therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates Graft Versus Host Disease (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

Key Topics Covered:

Graft Versus Host Disease (GVHD) - Overview
Graft Versus Host Disease (GVHD) - Therapeutics Development
Graft Versus Host Disease (GVHD) - Therapeutics Assessment
Graft Versus Host Disease (GVHD) - Companies Involved in Therapeutics Development
Graft Versus Host Disease (GVHD) - Drug Profiles
Graft Versus Host Disease (GVHD) - Dormant Projects
Graft Versus Host Disease (GVHD) - Discontinued Products
Graft Versus Host Disease (GVHD) - Product Development Milestones

Companies Mentioned

AbbVie Inc
Adienne Pharma & Biotech
AltruBio Inc
Amgen Inc
AnaptysBio Inc
apceth Biopharma GmbH
ASC Therapeutics Inc
AstraZeneca Plc
Athersys Inc
Autolus Therapeutics Plc
Bellicum Pharmaceuticals Inc
Biocon Ltd
Biogen Inc
BioIncept LLC
BioTheryX Inc
BlueRock Therapeutics
Boryung ViGenCell Inc
Bristol-Myers Squibb Co
Capricor Therapeutics Inc
Cellect Biotechnology Ltd
Cellective BioTherapy Inc
Cellix Bio Pvt Ltd
CheckPoint Immunology Inc
Clinigen Group Plc
CSL Ltd
CTI BioPharma Corp
Cytodyn Inc
Cytopeutics Pte Ltd
Daewoong Pharmaceutical Co Ltd
Dualogics Corp
Educell doo
Eli Lilly and Co
enGene Inc
Enlivex Therapeutics Ltd
Evive Biotech
ExCellThera Inc
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
Fujifilm Holdings Corp
Genentech USA Inc
GigaGen Inc
GlaxoSmithKline Plc
Glia LLC
Humanigen Inc
iCELL Biotechnology Co Ltd
Immplacate
Immune Modulation Inc
ImmuneTarget Inc
Imstem Biotechnology Inc
Incyte Corp
Inspyr Therapeutics Inc
Jazz Pharmaceuticals Plc
JN Biosciences LLC
Kadmon Corp LLC
Kalytera Therapeutics Inc
Kamada Ltd
Kiniksa Pharmaceuticals Ltd
Kymab Ltd
LG Chem Ltd
MaaT Pharma
Machavert Pharmaceuticals LLC
Magenta Therapeutics Inc
Mallinckrodt Plc
Medexus Pharmaceuticals Inc
Medicenna Therapeutics Corp
Mediolanum farmaceutici SpA
Medsenic SAS
Mereo Biopharma Group Plc
Mesoblast Ltd
Millennium Pharmaceuticals Inc
MitoImmune Therapeutics Inc
NapaJen Pharma Inc
Neovii Pharmaceuticals AG
Nurix Therapeutics Inc
OncoImmune Inc
OSE Immunotherapeutics
Panorama Research Inc
Pfizer Inc
Platinum Biotech (Beijing) Co Ltd
Pluristem Therapeutics Inc
Precision Biosciences Inc
REGiMMUNE Corp
SCM lifescience Co Ltd
Seattle Genetics Inc
Secura Bio Inc
Seres Therapeutics Inc
Shenzhen Chipscreen Biosciences Co Ltd
STERO Biotechs Ltd
StingInn LLC
Suzhou Connect Biopharmaceuticals Ltd
Suzhou Zelgen Biopharmaceutical Co Ltd
Syndax Pharmaceuticals Inc
Synthetic Biologics Inc
Takeda Pharmaceutical Co Ltd
Targazyme Inc
TCF GmbH
TeraImmune Inc
TGV Laboratories Inc
United BioPharma Inc
Vault Pharma Inc
Visterra Inc
Xenikos BV
Xenothera SAS
XL-protein GmbH

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/6sjh7b

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets